These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 12700383)

  • 1. Natalizumab for active Crohn's disease.
    Lew EA; Stoffel EM
    N Engl J Med; 2003 Apr; 348(16):1599; author reply 1599. PubMed ID: 12700383
    [No Abstract]   [Full Text] [Related]  

  • 2. Natalizumab for active Crohn's disease.
    Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
    N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
    Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab: a new hope for Crohn's disease?
    Napier J; Wong RK
    Am J Gastroenterol; 2003 May; 98(5):1197-9. PubMed ID: 12830820
    [No Abstract]   [Full Text] [Related]  

  • 5. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab for the treatment of Crohn's disease.
    Bickston SJ; Muniyappa K
    Expert Rev Clin Immunol; 2010 Jul; 6(4):513-9. PubMed ID: 20594122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab. Elan/Biogen.
    Elices MJ
    Curr Opin Investig Drugs; 2003 Nov; 4(11):1354-62. PubMed ID: 14758775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
    Ko HH; Bressler B
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Top-down versus Step-Up: new strategies in the treatment of Crohn's disease].
    Meier J; Sturm A
    Z Gastroenterol; 2009 Feb; 47(2):240-2. PubMed ID: 19197829
    [No Abstract]   [Full Text] [Related]  

  • 11. Investigational agents for Crohn's disease.
    Cottone M; Orlando A; Renna S
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1147-59. PubMed ID: 20836616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance infliximab infusions forever?
    Lee SD; Surawicz CM
    Am J Gastroenterol; 2002 Nov; 97(11):2917-8. PubMed ID: 12425570
    [No Abstract]   [Full Text] [Related]  

  • 13. [Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH].
    Tilg H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W;
    Z Gastroenterol; 2004 Oct; 42(10):1256-63. PubMed ID: 15508068
    [No Abstract]   [Full Text] [Related]  

  • 14. How effective are the usual treatments for Crohn's disease?
    Bebb JR; Scott BB
    Aliment Pharmacol Ther; 2004 Jul; 20(2):151-9. PubMed ID: 15233694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing infliximab therapy in pediatric Crohn's disease.
    Kirschner BS; Huo D
    Gastroenterology; 2007 Mar; 132(3):1167-70. PubMed ID: 17383435
    [No Abstract]   [Full Text] [Related]  

  • 16. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
    Sandborn WJ; Feagan BG; Lichtenstein GR
    Aliment Pharmacol Ther; 2007 Oct; 26(7):987-1003. PubMed ID: 17877506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease.
    Feagan BG; Sandborn WJ; Hass S; Niecko T; White J
    Am J Gastroenterol; 2007 Dec; 102(12):2737-46. PubMed ID: 18042106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Australian Crohn's antibiotic study opens new horizons.
    Gitlin L; Biesecker J
    Gastroenterology; 2007 Nov; 133(5):1743-4; author reply 1745-6. PubMed ID: 17983826
    [No Abstract]   [Full Text] [Related]  

  • 19. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
    Targan SR; Hanauer SB; van Deventer SJ; Mayer L; Present DH; Braakman T; DeWoody KL; Schaible TF; Rutgeerts PJ
    N Engl J Med; 1997 Oct; 337(15):1029-35. PubMed ID: 9321530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of Crohn's disease with anti TNF alpha antibodies--the experience in the Tel Aviv Medical Center].
    Dotan I; Yeshurun D; Hallak A; Horowitz N; Tiomny E; Reif S; Halpern Z; Rachmilewitz D
    Harefuah; 2001 Apr; 140(4):289-93, 368. PubMed ID: 11303390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.